Skip to content

Insight, China's Pharmaceutical Industry

Fineline Insights, Pharma Clarity

  • Home
  • About US
  • Bioinsight
  • Policy Hub
  • Deals Book
  • Privacy Policy
  • Contact US

Header Toggle Sidebar

This is an example widget to show how the Header Toggle Sidebar looks by default. You can add custom widgets from the widgets in the admin.

Company Deals

Shimai Pharmaceutical Files Hong Kong IPO Prospectus with Advanced T-Cell Engager Pipeline

Fineline Cube May 19, 2026
Company Deals

Youcare Pharmaceutical Commits $147M to Build Nucleic Acid Drug Manufacturing Base in Hangzhou Biopharma Town

Fineline Cube May 19, 2026
Company Deals

BrightGene Pursues Hong Kong Secondary Listing as Global API and Intermediates Leader

Fineline Cube May 19, 2026
Company Deals

Bayzed Health and Meinian Onehealth Forge Strategic Partnership to Build Integrated Full-Cycle Health Management Ecosystem

Fineline Cube May 19, 2026
Company Deals

Ande Healthcare Files Hong Kong IPO Prospectus as Leading Chinese Medical Consumables Innovator

Fineline Cube May 19, 2026
Policy / Regulatory

China Tightens Medical Insurance Personal Account Oversight with Mandatory “White List” for Retail Pharmacy Purchases

Fineline Cube May 19, 2026
Company Drug

Bayer’s HYRNUO Receives FDA Priority Review for First-Line HER2-Mutated NSCLC Treatment

Fineline Cube May 19, 2026
Company Drug

Sanegene Bio’s C3-Targeted siRNA SGB-9768 Expands to Hematological Disorders Following NMPA Clinical Trial Approval

Fineline Cube May 19, 2026
Company Drug

Mabwell Bioscience Receives NMPA Approval for 6MW3511 Clinical Trial in Solid Tumors

Fineline Cube Aug 24, 2022

China-based Mabwell (Shanghai) Bioscience Co., Ltd (SHA: 688062) announced that the National Medical Products Administration...

Company Drug

Bio-Thera Solutions Receives NMPA Approval for BAT8008 Clinical Trial in Solid Tumors

Fineline Cube Aug 24, 2022

Bio-Thera Solutions (SHA: 688177), a Guangzhou-based biotech firm, has received approval from the National Medical...

Company Drug

BeiGene’s Tislelizumab Receives 11th NMPA Filing for First-Line Esophageal Cancer

Fineline Cube Aug 24, 2022

BeiGene (NASDAQ: BGNE, HKG: 6160, SHA: 688235) announced that the National Medical Products Administration (NMPA)...

Company Drug

Innovent Biologics Doses First Patient in Australia Trial for PD-1/IL-2 Bispecific Antibody IBI363

Fineline Cube Aug 24, 2022

China-based Innovent Biologics, Inc. (HKG: 1801) announced that the first patient has been dosed in...

Company Deals

Lee’s Pharma Expands Global Rights to Windtree’s KL4 Surfactant Products

Fineline Cube Aug 24, 2022

China-based Lee’s Pharmaceutical Holdings Ltd (HKG: 0950) has expanded its licensing agreement with US-based Windtree...

Company Deals

Genetron Holdings Receives Buyout Offer from CEO Wang Sizhen at USD 1.36 per ADS

Fineline Cube Aug 24, 2022

Beijing-based precision oncology firm Genetron Holdings Ltd announced receipt of a buyout and take-private offer...

Drug Legal / IP

Supreme People’s Court Rules Against Chugai in China’s First Patent Linkage Case

Fineline Cube Aug 24, 2022

China’s Supreme People’s Court has delivered its verdict in the nation’s first patent linkage dispute,...

Company

Ascletis Pharma’s H1 2022 Revenue Rises 4.8% on R&D and Product Sales Growth

Fineline Cube Aug 23, 2022

Ascletis Pharma Inc. (HKG: 1672) reported RMB 38.2 million (USD 5.96 million) in revenue for...

Company Drug

Viatris Pharmaceuticals’ HIV/AIDS Drug Prioritized for CDE Review

Fineline Cube Aug 23, 2022

The Center for Drug Evaluation (CDE) has indicated that Viatris Pharmaceuticals Co., Ltd’s efavirenz/lamivudine/tenofovir is...

Company Deals

Hansoh Pharma Licenses GHDDI’s GDI-4405 for Global Development in COVID-19

Fineline Cube Aug 23, 2022

China-based Hansoh Pharmaceutical Group Co., Ltd (HKG: 3692) announced a licensing agreement with the Global...

Company Drug

Anhui Anke’s HK010 Bispecific Antibody Receives NMPA Review for Cancer Trials

Fineline Cube Aug 23, 2022

Anhui Anke Biotechnology (Group) Co., Ltd (SHE: 300009) announced that the National Medical Products Administration...

Company Deals

China-Based Firms Form Partnership to Advance Cell and Gene Therapy Ecosystem

Fineline Cube Aug 23, 2022

Six China-based companies—Porton Advanced Solutions Ltd, Shanghai Sequanta Biological Technology Co., Ltd, QuaCell Biotechnology Co.,...

Company Deals

BIOPSEE Series A+ Financing Confocal Microendoscope

Fineline Cube Aug 23, 2022

BIOPSEE, a Hubei-based microendoscope specialist, has raised tens of millions of renminbi in a Series...

Company Drug

CSPC Pharmaceutical’s DBPR108 Hits Endpoints in Type 2 Diabetes Trials

Fineline Cube Aug 23, 2022

China-based CSPC Pharmaceutical Group Ltd (HKG: 1093) announced that its Category 1 drug DBPR108 has...

Company Drug

Shanghai Pharmaceuticals Gets NMPA Approval for B013 in Triple-Negative Breast Cancer

Fineline Cube Aug 23, 2022

Shanghai Pharmaceuticals (HKG: 2607, SHA: 601607) has received approval from the National Medical Products Administration...

Company Drug

Scitop Bio-tech’s KEX02 Live Bacteria Therapy Gets FDA IND Approval for NSCLC

Fineline Cube Aug 23, 2022

Beijing Scitop Bio-tech Co., Ltd (SHE: 300858) announced that the US Food and Drug Administration...

Company Deals

Sanyou Biopharmaceuticals and KangaBio Ink Licensing Deal for Antibody Drug Candidate

Fineline Cube Aug 22, 2022

Shanghai-based Sanyou Biopharmaceuticals Co., Ltd and KangaBio have entered into a licensing agreement, granting Kanga...

Company

InnoCare Pharma’s 2022 Interim Report Shows Strong Revenue Growth Driven by Orelabrutinib Sales

Fineline Cube Aug 22, 2022

China-based InnoCare Pharma (HKG: 9969) announced its 2022 interim financial results, reporting total revenues of...

Company Deals

Porton Biologics Completes RMB 520M Series B to Expand Gene and Cell Therapy CDMO Platform

Fineline Cube Aug 22, 2022

Suzhou Porton Biologics Ltd, a China-based contract development and manufacturing organization (CDMO), announced the completion...

Company Drug

Nuance Pharma Gets NMPA Green Light for Ensifentrine COPD Trials in China

Fineline Cube Aug 22, 2022

China-based Nuance Pharma has secured approval from the National Medical Products Administration (NMPA) to conduct...

Posts pagination

1 … 635 636 637 … 668

Recent updates

  • Bayer’s HYRNUO Receives FDA Priority Review for First-Line HER2-Mutated NSCLC Treatment
  • Shimai Pharmaceutical Files Hong Kong IPO Prospectus with Advanced T-Cell Engager Pipeline
  • Sanegene Bio’s C3-Targeted siRNA SGB-9768 Expands to Hematological Disorders Following NMPA Clinical Trial Approval
  • Youcare Pharmaceutical Commits $147M to Build Nucleic Acid Drug Manufacturing Base in Hangzhou Biopharma Town
  • Hengrui’s HER3-Targeting ADC SHR-A2009 Achieves Phase III Success in EGFR-Mutated NSCLC After TKI Failure
Special Report 2025 Q1: U.S. Targets Chinese Pharma with 200% Tariffs—Will the Global Drug Market Collapse?

Category

  • Company
  • Deals
  • Digital
  • Drug
  • General/Other
  • Hospital
  • Legal / IP
  • Medical Device
  • Others
  • Policy / Regulatory
  • R&D

You Missed

Company Drug

Bayer’s HYRNUO Receives FDA Priority Review for First-Line HER2-Mutated NSCLC Treatment

Company Deals

Shimai Pharmaceutical Files Hong Kong IPO Prospectus with Advanced T-Cell Engager Pipeline

Company Drug

Sanegene Bio’s C3-Targeted siRNA SGB-9768 Expands to Hematological Disorders Following NMPA Clinical Trial Approval

Company Deals

Youcare Pharmaceutical Commits $147M to Build Nucleic Acid Drug Manufacturing Base in Hangzhou Biopharma Town

Insight, China's Pharmaceutical Industry

Fineline Insights, Pharma Clarity

Copyright © 2025 | Fineline Information & Technology | BlogData by Themeansar.